Translate Website | Traducir Sitio Web
Translate Website | Traducir Sitio Web
California law, pursuant to Health & Safety Code Sections §11480 & §11481, requires proposed research projects using certain opioid, stimulant, and hallucinogenic drugs classified as Schedule I and Schedule II Controlled Substances as their main study drug(s), to be reviewed and authorized by the Research Advisory Panel of California in the Attorney General's Office. See the Guidelines page for specific criteria.
The Research Advisory Panel primarily seeks to ensure the safety and protection of participating human research subjects and adequate security of the controlled substances used in the study. The Panel Members evaluate the scientific validity of each proposed project, and may reject proposals where the research is poorly conceived, would produce conclusions of little scientific value, or would not justify the exposure of California subjects to the risk of research.
During 2012 the Panel reviewed twenty-five research study submissions. Twenty-three were approved by the Panel. Among twenty-three approved studies, three studies were Academic research studies, two studies were Substance Abuse Treatment research protocols, and eighteen studies were Multi-Clinical Drug Trial research studies.
At the end of 2012, the Panel was monitoring 120 research projects.
Applicants may contact the Panel Office, or utilize the DEA Controlled Substance Listings link for further information on controlled substance schedules.
This Google™ translation feature is provided for informational purposes only.
The Office of the Attorney General is unable to guarantee the accuracy of this translation and is therefore not liable for any inaccurate information resulting from the translation application tool.
Please consult with a translator for accuracy if you are relying on the translation or are using this site for official business.
If you have any questions please contact:Bilingual Services Program at (916) 324-5482
A copy of this disclaimer can also be found on our Disclaimer page.
Close this box or use the [ X ]